Caligan Partners as of March 31, 2026
Portfolio Holdings for Caligan Partners
Caligan Partners holds 26 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 20.4 | $306M | 8.1M | 37.74 | |
| Revolution Medicines (RVMD) | 12.2 | $183M | 1.9M | 97.25 | |
| Abivax Sa Sponsored Ads (ABVX) | 10.8 | $163M | 1.5M | 111.35 | |
| Vaxcyte (PCVX) | 8.0 | $120M | 2.1M | 58.11 | |
| Xenon Pharmaceuticals (XENE) | 5.4 | $81M | 1.4M | 58.15 | |
| Mineralys Therapeutics (MLYS) | 5.0 | $75M | 2.8M | 27.09 | |
| Exelixis (EXEL) | 4.4 | $67M | 1.6M | 42.89 | |
| Cg Oncology Call Option (CGON) | 4.1 | $61M | 900k | 67.68 | |
| Tango Therapeutics (TNGX) | 3.4 | $50M | 2.4M | 20.92 | |
| Tyra Biosciences (TYRA) | 3.3 | $49M | 1.3M | 38.30 | |
| Adma Biologics (ADMA) | 3.0 | $46M | 5.1M | 9.01 | |
| Spyre Therapeutics Com New (SYRE) | 2.9 | $44M | 878k | 50.44 | |
| Lb Pharmaceuticals Com Shs (LBRX) | 2.3 | $35M | 1.4M | 24.08 | |
| Vor Biopharma Com New (VOR) | 2.3 | $34M | 1.9M | 17.84 | |
| Sab Biotherapeutics Com New (SABS) | 2.0 | $31M | 8.0M | 3.83 | |
| Ocuphire Pharma (IRD) | 1.8 | $28M | 6.1M | 4.55 | |
| Inventiva Sa Ads (IVA) | 1.8 | $28M | 5.0M | 5.55 | |
| Mbx Biosciences (MBX) | 1.7 | $25M | 849k | 29.85 | |
| Avalo Therapeutics Com New (AVTX) | 1.6 | $24M | 1.6M | 14.93 | |
| Anika Therapeutics (ANIK) | 1.4 | $21M | 1.4M | 14.50 | |
| Maze Therapeatics (MAZE) | 1.2 | $18M | 615k | 29.85 | |
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.3 | $4.9M | 924k | 5.29 | |
| Sensei Biotherapeutics Com New (SNSE) | 0.3 | $4.0M | 126k | 31.52 | |
| Agios Pharmaceuticals Call Option (AGIO) | 0.2 | $3.0M | 90k | 33.83 | |
| Aura Biosciences (AURA) | 0.1 | $1.5M | 230k | 6.69 | |
| Xilio Therapeutics | 0.1 | $943k | 112k | 8.41 |
